Takeda v. Colomba Therapeutics & Pharmascience: Colchicine Patent Suit Voluntarily Dismissed
Takeda Pharmaceutical filed suit in Delaware District Court asserting US7964648B2, covering methods for concomitant administration of colchicine with a second active agent, against Colomba Therapeutics and Pharmascience. Takeda voluntarily dismissed all claims without prejudice just 162 days after filing — before either defendant had answered or moved for summary judgment.
Takeda’s pre-answer colchicine dismissal leaves the door open
On 29 August 2024, Takeda Pharmaceutical Co., Ltd. filed an infringement action in the District of Delaware (Case No. 1:24-cv-00988) before Judge Richard G. Andrews, asserting US7964648B2 against Colomba Therapeutics, Inc. and Pharmascience, Inc. The patent covers methods for the concomitant administration of colchicine alongside a second active agent — a commercially significant claim in the context of branded gout and pericarditis therapies.
On 7 February 2025, Takeda filed a notice of voluntary dismissal under Fed. R. Civ. P. 41(a)(1)(A)(i), dismissing all claims against both defendants without prejudice. The procedural posture is significant: neither Colomba Therapeutics nor Pharmascience had filed an answer or a motion for summary judgment at the time of dismissal, meaning Takeda was entitled to dismiss as of right — no court approval was required.
The 162-day lifecycle and pre-answer exit are consistent with a strategic reassessment or parallel settlement discussion, though the public record does not disclose terms or the reason for withdrawal. Because the dismissal is without prejudice, Takeda retains the right to refile the same claims, which substantially preserves its enforcement position. What drove the decision — whether licensing, commercial negotiations, or a portfolio recalibration — remains unknown from publicly available filings.
Filing to Voluntary dismissal in 162 days
162 days — resolved before any defendant response was filed
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i) — dismissal as of right, no court order needed
Fed. R. Civ. P. 41(a)(1)(A)(i) permits a plaintiff to dismiss an action without a court order by filing a notice before the defendant serves an answer or a motion for summary judgment. Because neither Colomba Therapeutics nor Pharmascience had reached that procedural threshold, Takeda’s notice was self-executing. The case closed automatically upon filing — no judicial approval, no merits adjudication.
Pre-answer voluntary dismissalWithout prejudice: the critical distinction the public record confirms
A dismissal ‘without prejudice’ means Takeda’s infringement claims are not extinguished — it may refile the same action against either or both defendants in the future. A ‘with prejudice’ dismissal would have barred refiling permanently. The notice expressly states ‘without prejudice,’ so Takeda’s enforcement rights under US7964648B2 against these defendants remain intact. No estoppel or res judicata effect attaches.
Refiling rights preservedDefendants exit without a merits ruling — but face continued exposure
Colomba Therapeutics and Pharmascience avoided any finding of infringement or validity determination, which could be read as a tactical win. However, the without-prejudice dismissal means both parties remain exposed to re-assertion of US7964648B2. Any product development or commercialisation path involving colchicine co-administration methods must account for the continuing validity and enforceability of Takeda’s patent.
No merits finding; exposure continuesPatent remains live: colchicine co-administration space still under enforcement shadow
The withdrawal without prejudice signals that US7964648B2 has not been tested in litigation and its claims remain unchallenged by a court. For other generic or specialty pharma companies developing colchicine combination products, this case suggests Takeda is actively monitoring the space and willing to assert. The absence of a merits ruling means freedom-to-operate analysis against this patent remains essential for any market entrant.
Enforcement risk unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Takeda Pharmaceutical Co., Ltd. | Company | Global pharmaceutical company — holder of US7964648B2 covering colchicine co-administration methodsSearch in Eureka ↗ |
| Defendant | Colomba Therapeutics, Inc. | Company | Colomba Therapeutics, Inc. (drug developer) and Pharmascience, Inc. (Canadian generic manufacturer)Search in Eureka ↗ |
| Co-Defendant | Pharmascience, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrew S. Roper | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Edgar H. Haug | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Francis DiGiovanni | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Porter F. Fleming | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Thatcher A. Rahmeier | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Faegre Drinker Biddle & Reath LLP | Law Firm | Representing Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Cortlan S. Hitch | Attorney | Counsel for Colomba Therapeutics, Inc.Search in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Colomba Therapeutics, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Colomba Therapeutics, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) and expressly confirms the without-prejudice designation, while noting that neither defendant had answered or moved for summary judgment. This procedural framing is legally precise: it confirms the dismissal is self-executing and carries no merits weight. No claim construction, infringement finding, or validity ruling was issued. For both parties, the case ends without judicial estoppel, preserving full litigation optionality for Takeda and leaving both defendants without a declaratory judgment shield.
US7964648B2 — Colchicine Concomitant Administration Methods
US7964648B2, filed under application number US12/688038, covers methods for the concomitant administration of colchicine alongside a second active agent. Colchicine is a narrow therapeutic index drug used primarily in gout flare treatment and familial Mediterranean fever, with more recent applications in pericarditis. The patent’s focus on co-administration methods is strategically significant: it addresses the clinical reality that colchicine is frequently prescribed alongside other agents, including statins and other cardiovascular drugs, where drug-drug interaction management is critical.
For Takeda, US7964648B2 represents a method-of-treatment asset with broad applicability across colchicine-containing product lines, potentially including Colcrys. Method patents of this type are particularly potent in ANDA litigation because they can be asserted against generic manufacturers whose labels direct physicians toward the patented co-administration method. The patent has now been asserted in at least one active enforcement action, confirming Takeda views it as a commercially viable litigation asset — and any company formulating or distributing colchicine products in the US market should assess exposure carefully.
Should your colchicine product be cleared against US7964648B2?
Any pharmaceutical developer, generic manufacturer, or specialty pharma company with a colchicine product — particularly one prescribed or labelled for use alongside cardiovascular agents, anti-inflammatories, or other co-administered drugs — should assess exposure to US7964648B2. The patent’s method claims may be triggered by product labelling that instructs co-administration, even if the colchicine formulation itself is not novel. ANDA filers submitting Paragraph IV certifications face the highest immediate risk.
PatSnap Eureka’s FTO Search Agent allows R&D and regulatory teams to map claim scope against proposed product labelling and formulation data in real time. For US7964648B2 specifically, Eureka can identify overlapping prosecution history, prior art landscapes, and related method claims across Takeda’s portfolio — giving your team a data-driven basis for design-around decisions or IPR petition strategy before initiating costly development programmes.
Run a freedom-to-operate analysis on US7964648B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA and Colchicine Patent Suits in Delaware District Court
Explore related colchicine and small-molecule combination patent infringement cases filed in Delaware District Court, including comparable ANDA disputes and Rule 41 dismissals.
What this case signals for the colchicine and small-molecule combination IP landscape
Takeda’s pre-answer withdrawal preserves optionality — and sends a clear signal to the generic pharmaceutical sector.
Pre-answer dismissals often precede licensing deals or commercial resolution
When a pharma plaintiff exits before defendants have responded, it typically suggests the litigation served its strategic purpose — whether surfacing a licensing conversation or prompting defendants to pause commercialisation plans. The public record here is silent on terms, but the timing is consistent with an out-of-court resolution or strategic delay rather than a unilateral retreat.
US7964648B2 remains unlitigated and fully enforceable against new defendants
Because no court issued a validity or infringement ruling, the patent’s claims have not been tested in adversarial proceedings. Any company in the colchicine co-administration space — particularly generic ANDA filers — should treat this patent as an active enforcement risk. A without-prejudice dismissal resets the clock but does not reduce the patent’s legal potency.
Takeda v Colomba — key questions answered
It means Takeda’s infringement claims under US7964648B2 were dropped without any merits ruling and without extinguishing Takeda’s right to refile. The dismissal was entered under Rule 41(a)(1)(A)(i) before either defendant had answered, so it is self-executing and carries no res judicata or estoppel effect. Takeda retains full ability to reassert the same patent against the same defendants.
Takeda asserted US7964648B2, covering methods for the concomitant administration of colchicine and a second active agent. The patent was filed under application number US12/688038 and is relevant to colchicine-based therapies such as those used for gout and pericarditis where co-administration with other agents is clinically common.
The public record does not disclose the reason. However, pre-answer voluntary dismissals in pharmaceutical patent litigation are frequently consistent with out-of-court licensing discussions, commercial negotiations, or a decision to await further regulatory developments such as FDA approval milestones. The without-prejudice designation suggests Takeda preserved its options rather than abandoning its enforcement position.
Pharmascience is a Canadian generic pharmaceutical manufacturer with a US market presence. Its inclusion alongside Colomba Therapeutics typically suggests a potential ANDA-related filing or a Paragraph IV patent certification relating to a colchicine product. Generic manufacturers pursuing US market entry for colchicine combination products are prime targets for method-of-treatment patent assertions by branded holders like Takeda.
Yes. Because the dismissal was explicitly without prejudice under Rule 41(a)(1)(A)(i), Takeda faces no procedural bar to refiling the same claims against Colomba Therapeutics and Pharmascience in Delaware or another jurisdiction. However, a subsequent voluntary dismissal after an answer is filed could trigger with-prejudice effect under Rule 41. Defendants should monitor Takeda’s ANDA watch programme and FDA Orange Book listings for signals of renewed enforcement activity.
PatSnap Eureka searches patents and litigation data to answer instantly.